Literature DB >> 33740455

Antivirals with common targets against highly pathogenic viruses.

Lu Lu1, Shan Su1, Haitao Yang2, Shibo Jiang3.   

Abstract

Historically, emerging viruses appear constantly and have cost millions of human lives. Currently, climate change and intense globalization have created favorable conditions for viral transmission. Therefore, effective antivirals, especially those targeting the conserved protein in multiple unrelated viruses, such as the compounds targeting RNA-dependent RNA polymerase, are urgently needed to combat more emerging and re-emerging viruses in the future. Here we reviewed the development of antivirals with common targets, including those against the same protein across viruses, or the same viral function, to provide clues for development of antivirals for future epidemics.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33740455     DOI: 10.1016/j.cell.2021.02.013

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  30 in total

Review 1.  Beyond the vaccines: a glance at the small molecule and peptide-based anti-COVID19 arsenal.

Authors:  Kunal Nepali; Ram Sharma; Sachin Sharma; Amandeep Thakur; Jing-Ping Liou
Journal:  J Biomed Sci       Date:  2022-09-06       Impact factor: 12.771

2.  Broad-spectrum CRISPR-mediated inhibition of SARS-CoV-2 variants and endemic coronaviruses in vitro.

Authors:  Leiping Zeng; Yanxia Liu; Xammy Huu Nguyenla; Timothy R Abbott; Mengting Han; Yanyu Zhu; Augustine Chemparathy; Xueqiu Lin; Xinyi Chen; Haifeng Wang; Draven A Rane; Jordan M Spatz; Saket Jain; Arjun Rustagi; Benjamin Pinsky; Adrianna E Zepeda; Anastasia P Kadina; John A Walker; Kevin Holden; Nigel Temperton; Jennifer R Cochran; Annelise E Barron; Michael D Connolly; Catherine A Blish; David B Lewis; Sarah A Stanley; Marie F La Russa; Lei S Qi
Journal:  Nat Commun       Date:  2022-05-19       Impact factor: 17.694

Review 3.  The Immune System of Marine Organisms as Source for Drugs against Infectious Diseases.

Authors:  Alberto Falco; Mikolaj Adamek; Patricia Pereiro; David Hoole; José Antonio Encinar; Beatriz Novoa; Ricardo Mallavia
Journal:  Mar Drugs       Date:  2022-05-28       Impact factor: 6.085

4.  An orally available Mpro inhibitor is effective against wild-type SARS-CoV-2 and variants including Omicron.

Authors:  Bao-Xue Quan; Huiping Shuai; An-Jie Xia; Yuxin Hou; Rui Zeng; Xin-Lei Liu; Gui-Feng Lin; Jing-Xin Qiao; Wen-Pei Li; Fa-Lu Wang; Kai Wang; Ren-Jie Zhou; Terrence Tsz-Tai Yuen; Ming-Xin Chen; Chaemin Yoon; Ming Wu; Shi-Yu Zhang; Chong Huang; Yi-Fei Wang; Wei Yang; Chenyu Tian; Wei-Min Li; Yu-Quan Wei; Kwok-Yung Yuen; Jasper Fuk-Woo Chan; Jian Lei; Hin Chu; Shengyong Yang
Journal:  Nat Microbiol       Date:  2022-04-27       Impact factor: 30.964

5.  Lipopeptide-based pan-CoV fusion inhibitors potently inhibit HIV-1 infection.

Authors:  Qiaoshuai Lan; Jing Pu; Yanxing Cai; Jie Zhou; Lijue Wang; Fanke Jiao; Wei Xu; Qian Wang; Shuai Xia; Lu Lu; Shibo Jiang
Journal:  Microbes Infect       Date:  2021-05-19       Impact factor: 2.700

6.  Fludarabine Inhibits Infection of Zika Virus, SFTS Phlebovirus, and Enterovirus A71.

Authors:  Chengfeng Gao; Chunxia Wen; Zhifeng Li; Shuhan Lin; Shu Gao; Haida Ding; Peng Zou; Zheng Xing; Yufeng Yu
Journal:  Viruses       Date:  2021-04-27       Impact factor: 5.048

Review 7.  Recent advances in developing small-molecule inhibitors against SARS-CoV-2.

Authors:  Rong Xiang; Zhengsen Yu; Yang Wang; Lili Wang; Shanshan Huo; Yanbai Li; Ruiying Liang; Qinghong Hao; Tianlei Ying; Yaning Gao; Fei Yu; Shibo Jiang
Journal:  Acta Pharm Sin B       Date:  2021-07-02       Impact factor: 14.903

8.  Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation.

Authors:  Shuai Xia; Qiaoshuai Lan; Yun Zhu; Chao Wang; Wei Xu; Zhenghong Yuan; Youhua Xie; Fei Sun; Shibo Jiang; Lu Lu; Yutang Li; Lijue Wang; Fanke Jiao; Jie Zhou; Chen Hua; Qian Wang; Xia Cai; Yang Wu; Jie Gao; Huan Liu; Ge Sun; Jan Münch; Frank Kirchhoff
Journal:  Signal Transduct Target Ther       Date:  2021-07-29

9.  A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases.

Authors:  Jie Zhou; Wei Xu; Zezhong Liu; Chao Wang; Shuai Xia; Qiaoshuai Lan; Yanxing Cai; Shan Su; Jing Pu; Lixiao Xing; Youhua Xie; Lu Lu; Shibo Jiang; Qian Wang
Journal:  Acta Pharm Sin B       Date:  2021-08-02       Impact factor: 14.903

10.  Strategies to target SARS-CoV-2 entry and infection using dual mechanisms of inhibition by acidification inhibitors.

Authors:  Chaitra Prabhakara; Rashmi Godbole; Parijat Sil; Sowmya Jahnavi; Shah-E-Jahan Gulzar; Thomas S van Zanten; Dhruv Sheth; Neeraja Subhash; Anchal Chandra; Akshatha Shivaraj; Patricia Panikulam; Ibrahim U; Vijay Kumar Nuthakki; Theja Parassini Puthiyapurayil; Riyaz Ahmed; Ashaq Hussain Najar; Sai Manoz Lingamallu; Snigdhadev Das; Bhagyashri Mahajan; Praveen Vemula; Sandip B Bharate; Parvinder Pal Singh; Ram Vishwakarma; Arjun Guha; Varadharajan Sundaramurthy; Satyajit Mayor
Journal:  PLoS Pathog       Date:  2021-07-12       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.